Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Sponsor: Sorrento Therapeutics, Inc.
This PHASE1/PHASE2 trial investigates Light Chain (AL) Amyloidosis and is currently ongoing. Sorrento Therapeutics, Inc. leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Feb 2025 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
▶ Show 7 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sorrento Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .